Tissue Penetration of Antifungal Agents

被引：306
作者：
Felton, Timothy [1 ,2 ]
Troke, Peter F. [3 ]
Hope, William W. [2 ]
机构：
[1] Univ Manchester, Acad Hlth Sci Ctr, Univ Hosp South Manchester NHS Fdn Trust, Manchester, Lancs, England
[2] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England
[3] Old Court, Kingsgate, Kent, England
来源：
CLINICAL MICROBIOLOGY REVIEWS | 2014年 / 27卷 / 01期
基金：
英国医学研究理事会;
关键词：
LIPOSOMAL AMPHOTERICIN-B; BLOOD-BRAIN-BARRIER; HEMATOGENOUS CANDIDA MENINGOENCEPHALITIS; BODY-FLUID CONCENTRATIONS; F-18 LABELED FLUCONAZOLE; CRITICALLY-ILL PATIENTS; CEREBROSPINAL-FLUID; LIPID FORMULATIONS; INTRAPULMONARY PHARMACOKINETICS; DOUBLE-BLIND;
D O I：
10.1128/CMR.00046-13
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Understanding the tissue penetration of systemically administered antifungal agents is critical for a proper appreciation of their antifungal efficacy in animals and humans. Both the time course of an antifungal drug and its absolute concentrations within tissues may differ significantly from those observed in the bloodstream. In addition, tissue concentrations must also be interpreted within the context of the pathogenesis of the various invasive fungal infections, which differ significantly. There are major technical obstacles to the estimation of concentrations of antifungal agents in various tissue subcompartments, yet these agents, even those within the same class, may exhibit markedly different tissue distributions. This review explores these issues and provides a summary of tissue concentrations of 11 currently licensed systemic antifungal agents. It also explores the therapeutic implications of their distribution at various sites of infection.
引用
收藏
页码：68 / 88
页数：21
相关论文
共 260 条
[1]  
Aboagye EO, 1998, CANCER RES, V58, P4075
[2]   Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase I and phase II studies [J].
Adedoyin, A ;
Bernardo, JF ;
Swenson, CE ;
Bolsack, LE ;
Horwith, G ;
DeWit, S ;
Kelly, E ;
Klasterksy, J ;
Sculier, JP ;
DeValeriola, D ;
Anaissie, E ;
LopezBerestein, G ;
LlanosCuentas, A ;
Boyle, A ;
Branch, RA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2201-2208
[3]   Congestive heart failure associated with itraconazole [J].
Ahmad, SR ;
Singer, SJ ;
Leissa, BG .
LANCET, 2001, 357 (9270) :1766-1767
[4]   A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients [J].
Ally, R ;
Schürmann, D ;
Kreisel, W ;
Carosi, G ;
Aguirrebengoa, K ;
Dupont, B ;
Hodges, M ;
Troke, P ;
Romero, AJ .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) :1447-1454
[5]   Animal model pharmacokinetics and pharmacodynamics: a critical review [J].
Andes, D ;
Craig, WA .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :261-268
[6]   Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models [J].
Andes, D ;
Safdar, N ;
Marchillo, K ;
Conklin, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) :674-684
[7]  
Andes David, 2003, Curr Opin Investig Drugs, V4, P991
[8]   Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials [J].
Andes, David R. ;
Safdar, Nasia ;
Baddley, John W. ;
Playford, Geoffrey ;
Reboli, Annette C. ;
Rex, John H. ;
Sobel, Jack D. ;
Pappas, Peter G. ;
Kullberg, Bart Jan .
CLINICAL INFECTIOUS DISEASES, 2012, 54 (08) :1110-1122
[9]  
Aoyama Takahiko, 2005, Drug Metab Pharmacokinet, V20, P485, DOI 10.2133/dmpk.20.485
[10]   Randomized, double-blind, Multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases [J].
Arathoon, EG ;
Gotuzzo, E ;
Noriega, LM ;
Berman, RS ;
DiNubile, MJ ;
Sable, CA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :451-457
12345678910